osk ah il bx ensg ensmusg nmnm nmnm npnp npnp ctla ctla cytotox tlymphocyteassoci protein also know cd cluster differenti protein receptor function immun checkpoint downregul immun respons ctla constitut express regulatori cell upregul convent cell activ phenomenon particular notabl cancer act switch bind cd cd surfac antigenpresent cell ctla protein encod ctla gene mous ctla gene human ctla first identifi second receptor cell costimul ligand novemb lab tak wah mak arlen sharp independ publish find discoveri function ctla negat regul tcell activ knock gene mous previous studi sever lab use method could definit defin function ctla contradictori ctla member immunoglobulin superfamili express activ cell transmit inhibitori signal cell ctla homolog tcell costimulatori protein cd molecul bind cd cd also call respect antigenpresent cell ctla bind cd cd great affin avid cd thus enabl outcompet cd ligand ctla transmit inhibitori signal cell wherea cd transmit stimulatori signal ctla also find regulatori cell treg contribut inhibitori function cell activ cell receptor cd lead increas express ctla mechan ctla act cell remain somewhat controversi biochem evid suggest ctla recruit phosphatas cell receptor tcr thus attenu signal work remain unconfirm literatur sinc first public recent work suggest ctla may function vivo captur remov cd cd membran antigenpresent cell thus make unavail trigger cd addit find dendrit cell dc treg interact caus sequestr fascin actinbundl protein essenti immunolog synaps format skew fascindepend actin polar antigen present dc toward treg cell adhes zone although revers upon regulatori cell disengag sequestr essenti cytoskelet compon caus letharg state dc lead reduc cell prime suggest tregmedi immun suppress multistep process addit ctla cdcd interact fascindepend polar cytoskeleton toward dctreg immun synaps may play pivot role ctla may also function via modul cell motil andor signal pi kinas earli multiphoton microscopi studi observ tcell motil intact lymph node appear give evid socal reversestop signal model model ctla revers tcrinduc stop signal need firm contact cell antigenpresent cell apc howev studi compar ctla posit cell predomin regulatori cell least partial activ ctla negat naiv cell dispar cell multipl regard may explain result group analyz effect antibodi ctla vivo conclud littl effect upon motil context anerg tcell antibodi ctla may exert addit effect use vivo bind therebi deplet regulatori cell protein contain extracellular domain transmembran domain cytoplasm tail altern splice variant encod differ isoform character membranebound isoform function homodim interconnect disulfid bond solubl isoform function monom intracellular domain similar cd intrins catalyt activ contain one yvkm motif abl bind pik ppa shp one prolinerich motif abl bind sh contain protein first role ctla inhibit cell respons seem direct via shp ppa dephosphoryl tcrproxim signal protein cd lat ctla also affect signal indirect via compet cd cd bind ctla also bind pik although import result interact uncertain variant gene associ type diabet grave diseas hashimoto thyroid celiac diseas system lupus erythematosus thyroidassoci orbitopathi primari biliari cirrhosi autoimmun diseas polymorph ctla gene associ autoimmun diseas rheumatoid arthriti autoimmun thyroid diseas multipl sclerosi though associ often weak system lupus erythematosus sle splice variant sctla find aberr produc find serum patient activ sle germlin haploinsuffici ctla lead ctla defici chai diseas ctla haploinsuffici autoimmun infiltr rare genet disord immun system may caus dysregul immun system may result lymphoprolifer autoimmun hypogammaglobulinemia recurr infect may slight increas one risk lymphoma ctla mutat first describ collabor group dr gulbu uzel dr steven holland dr michael lenardo nation institut allergi infecti diseas dr thoma fleisher nih clinic center nation institut health collabor year collabor group dr bodo grimbach dr shimon sakaguchi dr luci walker dr david sansom collabor describ similar phenotyp ctla mutat inherit autosom domin manner mean person need one abnorm gene one parent one normal copi enough compens one abnorm copi domin inherit mean famili ctla mutat affect relat generat side famili mutat symptomat patient ctla mutat character immun dysregul syndrom includ extens cell infiltr number organ includ gut lung bone marrow central nervous system kidney patient diarrhea enteropathi lymphadenopathi hepatosplenomegali also common autoimmun organ affect autoimmun vari includ thrombocytopenia hemolyt anemia thyroid type diabet psoriasi arthriti respiratori infect also common import clinic present diseas cours variabl individu sever affect wherea show littl manifest diseas variabl express even within famili strike may explain differ lifestyl exposur pathogen treatment efficaci genet modifi condit describ incomplet penetr diseas penetr say incomplet individu fail express trait seem complet asymptomat even though carri allel penetr estim clinic symptom caus abnorm immun system patient develop reduc level least one immunoglobulin isotyp low ctla protein express regulatori cell hyperactiv effector cell low switch memori cell progress loss circul cell diagnosi make treatment base individu clinic condit may includ standard manag autoimmun immunoglobulin defici studi report treat korean chai diseas patient abatacept fusion protein ctla antibodi abl control immun activ improv patient symptom regular administr abatacept improv patient sever anemia diarrhea lday bring yearlong hospit end compar high bind affin ctla cd make potenti therapi autoimmun diseas fusion protein ctla antibodi ctlaig use clinic trial rheumatoid arthriti fusion protein ctlaig commerci avail orencia abatacept second generat form ctlaig know belatacept recent approv fda base favor result random phase iii benefit belatacept evalu nephroprotect efficaci first line immunosuppress trial studi approv renal transplant patient sensit epsteinbarr virus ebv convers increas interest possibl therapeut benefit block ctla use antagonist antibodi ctla ipilimumabfda approv melanoma mean inhibit immun system toler tumour therebi provid potenti use immunotherapi strategi patient cancer therapi first approv immun checkpoint blockad therapi anoth yet approv tremelimumab nobel prize physiolog medicin award jame allison tasuku honjo discoveri cancer therapi inhibit negat immun regul ctla show interact ah ctla nmr structur crystal structur ctlab complex il human bctla costimulatori complex articl incorpor text unit state nation librari medicin public domain